Zicam study
This article was originally published in The Tan Sheet
Executive Summary
Homeopathic remedy found significantly to improve seasonal allergic rhinitis symptoms in a double-blind, placebo-controlled study involving 32 patients, according to Sion Noble, MD, Mission Hills Medical Center, Calif. The peer-reviewed pilot study, published in the August Internet Journal of Family Practice, finds Gum Tech's Zicam Allergy Relief nasal gel improves quality of life for allergic rhinitis sufferers in several categories: activities (social, work, recreational), sleep, emotions, nasal symptoms, ocular symptoms, non-ocular/non-nasal symptoms and practical problems. Quality of life and effect on activity improved 52% and 49.3%, respectively, over the two-week period. NAD recently dismissed an ad challenge involving Zicam cold claims despite concerns regarding substantiation for the claims (1"The Tan Sheet" May 15, In Brief)
You may also be interested in...
NAD dismisses Zicam case
Quigley's use of Gel Tech's submissions to NAD as evidence in its federal court proceeding against Zicam has caused the Council of Better Business Bureaus' National Advertising Division to close its review of Gel Tech's ad claims for Zicam Cold Remedy without issuing a decision. Quigley, the marketer of Cold-Eeze lozenges and challenger of the Zicam claims, violated their confidentiality agreement through its actions, NAD says (1"The Tan Sheet" April 24, p. 8). NAD notes it had "concerns" about whether the claims, including "highly effective cold remedy" and "reduce the duration of the common cold," were adequately supported
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands